Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Length Mouse Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant Mice

No abstract is available for this paper.

• Publication year

  2009

• Venue

  HYPERTENSION

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/HYPERTENSIONAHA.109.134668PMID 19786649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats.

  2009cited by this paper
• Placental growth factor is a potent vasodilator of rat and human resistance arteries.

  2008cited by this paper
• Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia

  2008cited by this paper
• Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.

  2007cited by this paper
• Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia

  2007cited by this paper
• The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice.

  2007cited by this paper
• Alterations in Placental Growth Factor Levels before and after the Onset of Preeclampsia Are More Pronounced in Women with Early Onset Severe Preeclampsia

  2007cited by this paper
• Role of the VEGF-A Signaling Pathway in the Glomerulus: Evidence for Crosstalk between Components of the Glomerular Filtration Barrier

  2007cited by this paper
• Gender-specific effect of overexpression of sFlt-1 in pregnant mice on fetal programming of blood pressure in the offspring later in life.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Soluble endoglin contributes to the pathogenesis of preeclampsia

  2006cited by this paper
• A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity.

  2006cited by this paper
• Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

  2006cited by this paper
• Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2.

  2006cited by this paper
• Increased collagen content in insulin-resistant skeletal muscle.

  2006cited by this paper
• The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.

  2005cited by this paper
• Circulating Angiogenic Factors and the Risk of Preeclampsia

  2005cited by this paper
• Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IkappaB/NF-kappaB.

  2004cited by this paper
• Circulating angiogenic factors and the risk of preeclampsia.

  2004cited by this paper
• Vascular Endothelial Growth Factor-mediated Induction of Manganese Superoxide Dismutase Occurs through Redox-dependent Regulation of Forkhead and IκB/NF-κB*

  2004cited by this paper
• Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Prospective Analysis of Placenta Growth Factor (PlGF) Concentrations in the Plasma of Women with Normal Pregnancy and Pregnancies Complicated by Preeclampsia

  2004cited by this paper
• Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis.

  2004cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• Glomerular endotheliosis in normal pregnancy and pre‐eclampsia

  2003cited by this paper
• A critical role of placental growth factor in the induction of inflammation and edema formation.

  2003cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) could contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

  2003cited by this paper
• Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria*

  2003cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians.

  2002cited by this paper
• KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF

  2002cited by this paper
• Exaggerated Hypotensive Effect of Vascular Endothelial Growth Factor in Spontaneously Hypertensive Rats

  2002cited by this paper
• Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

  2001cited by this paper
• Immuno-electron microscopic localization of endothelial nitric oxide synthase in human placental terminal villous trophoblasts-normal and pre-eclamptic pregnancy.

  2001cited by this paper
• Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards.

  2001cited by this paper
• Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene.

  2000cited by this paper
• Causes of maternal mortality in Japan.

  2000cited by this paper
• A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation.

  1998cited by this paper
• Mapping of the Sites Involved in Ligand Association and Dissociation at the Extracellular Domain of the Kinase Insert Domain-containing Receptor for Vascular Endothelial Growth Factor*

  1998cited by this paper
• Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors.

  1998cited by this paper
• Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1*

  1997cited by this paper
• Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.

  1996cited by this paper
• Assessment of fetal compromise by Doppler ultrasound investigation of the fetal circulation. Arterial, intracardiac, and venous blood flow velocity studies.

  1995cited by this paper
• Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial.

  1994cited by this paper
• Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.

  1994cited by this paper
• Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.

  1993cited by this paper
• Glomerular capillary endotheliosis in toxemia of pregnancy.

  1959cited by this paper

• Evaluating the sFlt1 Mouse Model of Preeclampsia: Benefits and Limitations for Understanding Human Disease

  2025cites this paper
• Complement factor H-point mutation promotes the development of preeclampsia-like phenotype with multiparity in mice.

  2025cites this paper
• VEGFR1 as a Target for Cardiovascular Gene Therapy

  2025cites this paper
• Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road

  2024cites this paper
• Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach

  2023cites this paper
• Approaches to modeling placental function in preeclampsia in vitro and in vivo.

  2023cites this paper
• Impact of adverse gestational milieu on maternal cardiovascular health.

  2023cites this paper
• Lipid Nanoparticle Composition Drives mRNA Delivery to the Placenta

  2022cites this paper
• The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia.

  2022cites this paper
• Current State of Preeclampsia Mouse Models: Approaches, Relevance, and Standardization

  2021cites this paper
• Placental mitochondrial function as a driver of angiogenesis and placental dysfunction

  2021cites this paper
• Progress in preeclampsia: the contribution of animal models

  2021cites this paper
• Superovulation with human chorionic gonadotropin (hCG) trigger and gonadotropin releasing hormone agonist (GnRHa) trigger differentially alter essential angiogenic factors in the endometrium in a mouse ART model†

  2020cites this paper
• The bioflavonoid quercetin improves pathophysiology in a rat model of preeclampsia.

  2020cites this paper
• Animal Models of Preeclampsia

  2020cites this paper
• Effect of placental growth factor in models of experimental pre‐eclampsia and trophoblast invasion

  2020cites this paper
• Clinically Relevant High Levels of Human C-Reactive Protein Induces Endothelial Dysfunction and Hypertension by Inhibiting the AMPK-eNOS Axis.

  2020cites this paper
• Regulation of Uterine Spiral Artery Remodeling: a Review

  2020cites this paper
• Pravastatin for preeclampsia: From animal to human

  2020cites this paper
• Low molecular weight heparin promotes transcription and release of placental growth factor from endothelial cells.

  2020cites this paper
• Preeclampsia: Maternal Systemic Vascular Disorder Caused by Generalized Endothelial Dysfunction Due to Placental Antiangiogenic Factors

  2019cites this paper
• Placental growth factor blunts uterine artery responses to angiotensin II

  2019cites this paper
• Adult Pgf−/− mice behaviour and neuroanatomy are altered by neonatal treatment with recombinant placental growth factor

  2019cites this paper
• Narrowing abdominal aorta and vein is a simple and useful method for preparing a mice model of gestational hypertension

  2019cites this paper
• The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases

  2019cites this paper
• Targeting the vascular dysfunction: Potential treatments for preeclampsia

  2019cites this paper
• Preeclampsia link to gestational hypoxia

  2019cites this paper
• Low‐dose aspirin reduces hypoxia‐induced sFlt1 release via the JNK/AP‐1 pathway in human trophoblast and endothelial cells

  2019cites this paper
• Animal models of preeclampsia: translational failings and why.

  2018cites this paper
• Pro-angiogenic therapeutics for preeclampsia

  2018cites this paper
• Neurodevelopment at Age 10 Years of Children Born <28 Weeks With Fetal Growth Restriction

  2017cites this paper
• Vascular damage and dysfunction in hypertensive emergencies

  2017cites this paper
• Is Canada Ready to Adopt Maternal Placental Growth Factor Testing to Improve Clinical Outcomes for Women with Suspected Preeclampsia?

  2017cites this paper
• Preeclampsia: A review of the pathogenesis and possible management strategies based on its pathophysiological derangements.

  2017cites this paper
• Placental growth factor and pre-eclampsia

  2017cites this paper
• Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction

  2017cites this paper
• Changes in Central Hemodynamics in Women With Hypertensive Pregnancy Between Before and After Delivery

  2016cites this paper
• Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates

  2016cites this paper
• Angiogenic Factors in Preeclampsia From Diagnosis to Therapy

  2016cites this paper
• Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy

  2016cites this paper
• Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia

  2016cites this paper
• Establishment of ApoE-knockout mouse model of preeclampsia and relevant mechanisms

  2016cites this paper
• Angiogenic Factors in Preeclampsia: From Diagnosis to Therapy.

  2016cites this paper
• Placental abnormalities and hypertension in pregnancy

  2015cites this paper
• Pathogenesis of preeclampsia

  2015cites this paper
• Full-Length Human Placental sFlt-1-e15a Isoform Induces Distinct Maternal Phenotypes of Preeclampsia in Mice

  2015cites this paper
• Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor.

  2014cites this paper
• New approaches for managing preeclampsia: clues from clinical and basic research.

  2014cites this paper
• In Vivo Experiments Reveal the Good, the Bad and the Ugly Faces of sFlt-1 in Pregnancy

  2014cites this paper
• Mesenchymal Stem Cells Ameliorate Th1-Induced Pre-Eclampsia-Like Symptoms in Mice via the Suppression of TNF-α Expression

  2014cites this paper
• SFlt-1 Elevates Blood Pressure by Augmenting Endothelin-1-Mediated Vasoconstriction in Mice

  2014cites this paper
• Carbon Monoxide Prevents Hypertension and Proteinuria in an Adenovirus sFlt-1 Preeclampsia-Like Mouse Model

  2014cites this paper
• Maternally sequestered therapeutic polypeptides – a new approach for the management of preeclampsia

  2014cites this paper
• Increased antiangiogenetic factors in severe proteinuria without hypertension in pregnancy: is kidney biopsy necessary?

  2014cites this paper
• Circulating endothelial progenitor cells and placental abruption in women with preeclampsia.

  2014cites this paper
• Animal Models of Preeclampsia: Insight into Possible Biomarker Candidates for Predicting Preeclampsia

  2014cites this paper
• LOW-DOSE CARBON MONOXIDE EXPOSURE IN PREGNANCY; A POTENTIAL THERAPEUTIC FOR PRE-ECLAMPSIA

  2014cites this paper
• New developments in the pathogenesis of preeclampsia.

  2013cites this paper
• Endoglin: a critical mediator of cardiovascular health

  2013cites this paper
• Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards?

  2013cites this paper
• Angiogenic defects in preeclampsia: What is known, and how are such defects relevant to preeclampsia pathogenesis?

  2013cites this paper
• Angiogenic factors in preeclampsia: potential for diagnosis and treatment

  2013cites this paper
• STOX1: a new player in preeclampsia?

  2013cites this paper
• Vascular Health and Risk Management Endoglin : a critical mediator of cardiovascular health

  2013cites this paper
• Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19–31 weeks of gestation

  2013cites this paper
• Association of Angiotensinogen Gene Polymorphisms and Angiogenic Factors with Preeclampsia in Chinese Women

  2013cites this paper
• The vascular endothelial growth factor family in adverse pregnancy outcomes.

  2012cites this paper
• Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1.

  2012cites this paper
• Angiogenesis and Preeclampsia

  2012cites this paper
• PlGF: a multitasking cytokine with disease-restricted activity.

  2012cites this paper
• The Impact of Magnesium Sulfate Therapy on Angiogenic Factors in Preeclampsia.

  2012cites this paper
• Threshold of Soluble Fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio for the Imminent Onset of Preeclampsia

  2011cites this paper
• VEGF: a possible therapeutic for the treatment of preeclampsia?

  2011cites this paper
• Endothelin: key mediator of hypertension in preeclampsia.

  2011cites this paper
• Nitric oxide generation affects pro- and anti-angiogenic growth factor expression in primary human trophoblast.

  2011cites this paper
• Induction of Heme Oxygenase 1 Attenuates Placental Ischemia–Induced Hypertension

  2011cites this paper
• Angiogenic factors and preeclampsia.

  2011cites this paper
• Gestational hypertension as a subclinical preeclampsia in view of serum levels of angiogenesis-related factors

  2011cites this paper
• Is inflammation the cause of pre-eclampsia?

  2011cites this paper
• Alternate processing of Flt1 transcripts is directed by conserved cis-elements within an intronic region of FLT1 that reciprocally regulates splicing and polyadenylation

  2010cites this paper
• Recent insights into the pathophysiology of preeclampsia.

  2010cites this paper
• Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia

  2010cites this paper
• Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model

  2010cites this paper
• Pre-eclampsia: connecting angiogenic and metabolic pathways

  2010cites this paper